Evidence map›Paper›PMID 24623658›Full record

ArticleAdvanced healthcare materials2014

Lipid-like nanomaterials for simultaneous gene expression and silencing in vivo.

Yizhou Dong, Ahmed A Eltoukhy, Christopher A Alabi, Omar F Khan, Omid Veiseh, J Robert Dorkin, Sasilada Sirirungruang, Hao Yin, Benjamin C Tang, Jeisa M Pelet and 5 more

Abstract read
In one paragraph

Article in Advanced healthcare materials, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. In vivo targeted delivery of nucleic acids and CRISPR genome editors enabled by GSH-responsive silica nanoparticles.Journal of controlled release : official journal of the Controlled Release Society · 2021
    Article
  10. Delivery of eupenifeldin via polymer-coated surgical buttresses prevents local lung cancer recurrence.Journal of controlled release : official journal of the Controlled Release Society · 2021
    Article
  11. Review
  12. Article
  13. Nanoscale platforms for messenger RNA delivery.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2019
    Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Preparation and Optimization of Lipid-Like Nanoparticles for mRNA Delivery.Methods in molecular biology (Clifton, N.J.) · 2017
    Article
  20. Nanoparticles for siRNA-Based Gene Silencing in Tumor Therapy.IEEE transactions on nanobioscience · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Yizhou DongDavid H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA; Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA; Department of Anesthesiology, Children's Hospital Boston, 300 Longwood Avenue, Boston, MA, 02115, USA.
Ahmed A Eltoukhy
Christopher A Alabi
Omar F Khan
Omid Veiseh
J Robert Dorkin
Sasilada Sirirungruang
Hao Yin
Benjamin C Tang
Jeisa M Pelet
Delai Chen
Zhen Gu
Yuan Xue
Robert Langer
Daniel G Anderson

Funding

The Development of Clinical Grade, Targeted Magnetic NanoparticlesU54CA151884 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI LANGER, ROBERT SAMUEL · 2010 to 2014
$11.3M
CONTROLLED RELEASE OF MACROMOLECULESR01EB000244 · NIBIB · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI LANGER, ROBERT SAMUEL, TRAVERSO, CARLO GIOVANNI · 2002 to 2021
$6.1M
Controlled Release of MacromoleculesR37EB000244 · NIBIB · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI LANGER, ROBERT SAMUEL · 2008 to 2017
$3.9M
High-Throughput Craniofacial tissue engineeringR01DE016516 · NIDCR · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI LANGER, ROBERT SAMUEL · 2005 to 2014
$3.8M
Targeted Nanoparticle DNA Therapy for Ovarian CancerR01CA132091 · NCI · LANKENAU INSTITUTE FOR MEDICAL RESEARCH · PI SAWICKI, JANET A · 2008 to 2012
$1.4M
Lipidoid Nanoparticles with Simultaneous Multi-Gene Regulation for Cancer TherapyF32EB017625 · NIBIB · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI DONG, YIZHOU · 2013 to 2013
$56k
NCI NIH HHS 5-R01-CA132091-04NCI NIH HHS R01 CA132091NCI NIH HHS U54 CA151884NCI NIH HHS U54-CA151884NHLBI NIH HHS HHSN268201000045CNIBIB NIH HHS 1F32EB017625NIBIB NIH HHS F32 EB017625NIBIB NIH HHS R01 EB000244NIBIB NIH HHS R01-EB000244-27NIBIB NIH HHS R37 EB000244NIDCR NIH HHS R01 DE016516NIDCR NIH HHS R01-DE016516-03
6 · The paper itself

Abstract

New lipid-like nanomaterials are developed to simultaneously regulate expression of multiple genes. Self-assembled nanoparticles are capable of efficiently encapsulating pDNA and siRNA. These nanoparticles are shown to induce simultaneous gene expression and silencing both in vitro and in vivo.

Indexed as

Gene ExpressionGene SilencingAnimalsHeLa CellsHumansLipidsMiceMice, Inbred C57BLNanostructuresRNA, Small InterferingTransfectionTriazinesLipidsRNA, Small InterferingTriazinesgene expressiongene silencinglipid-like nanomaterialsplasmid DNAsiRNA

Identifiers

PMID24623658
PMCPMC4160381

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.